Growblox Sciences Inc (OP: GBLX )
0.0560 USD +0.0042 (+8.11%) Streaming Delayed Price Updated: 10:55 AM EST, Jan 22, 2021 Add to My Watchlist
Press releases about Growblox Sciences Inc
Data Shows Medical Cannabis Market Value is Set to Grow
June 07, 2018
Quality and consistency of raw materials to research, manufacture and deliver trusted medical-cannabis formulations has been the single largest stumbling block for cannabis-based medical formulations...
GB Sciences Will Now Serve A Greatly Expanded Patient Base In Louisiana With The Addition Of Autism, Glaucoma, Parkinson's, PTSD, Intractable Pain And Severe Muscle Spasms To The List Of Ailments Cove
May 21, 2018
GB Sciences, Inc. (OTCQB:GBLX), it all started with one woman's plea and ended with a call to action for a dramatic expansion of diseases treated by medical cannabis throughout the State of Louisiana.
GB Sciences' Acquisition Of NevadaPURE Is Terminated
May 09, 2018
GB Sciences, Inc. (OTCQB: GBLX), the previously announced proposed acquisition of NevadaPURE, LLC, a Nevada limited liability company, by GB Sciences has been terminated. In accordance with the terms...
CannabisNewsAudio – Global Payout, Inc. (GOHE) Prepares to Meet Rising Demand for Cannabis Payment Solutions
May 04, 2018
CannabisNewsAudio – Global Payout, Inc. (GOHE) Offers Cannabis Companies Unique Payment and Consulting Services
April 27, 2018
CannabisNewsAudio – Global Payout, Inc. (GOHE) Offers Alternative to Traditional Banking with Fintech Solutions
April 20, 2018
GB Sciences, CEO, John Poss, Joins Everett Jolly on Uptick Newswire’s “Stock Day” Podcast
April 19, 2018
GB Sciences, Inc. (OTCQB:GBLX) (“the “Company”), today announced CEO, John Poss, returned to Uptick Newswire’s “Stock Day” podcast with Everett Jolly for an operational update.
Exploratory IND Is Planned Using GB Sciences' Proprietary Mixtures of Botanical Compounds to Provide the Highest Efficacy for Patients
April 16, 2018
GB Sciences, Inc. (OTCQB: GBLX), as previously reported, plans to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data, to support clinical development...
GB Sciences Announces the Appointment of John B. Davis as Executive VP and General Counsel
April 11, 2018
GB Sciences, Inc. (OTCQB: GBLX), a company that marries cutting edge cannabis cultivation and biopharmaceutical research and development, announced today that it has appointed John B. Davis as...
GB Sciences Pursues FDA-Registered, First-in-Human Trial of Cannabis-based Therapy for Parkinson's Disease
April 09, 2018
GB Sciences, Inc. (OTCQB: GBLX) is planning to file an Exploratory IND and perform a Phase 0 Clinical Trial to gather valuable First-In-Human data on its proprietary cannabis-based therapies for the...
GB Sciences Completes Nanotechnology Transfer of Exclusively-Licensed, Cannabinoid-Based, Time-Released Neuropathic Pain Formula
April 03, 2018
GB Sciences, Inc. (OTCQB: GBLX) has completed the technology transfer for the manufacturing of time-released nanoparticles containing a cannabinoid-based therapeutic for neuropathic pain from the...
Forecast Indicates CBD Global Market Projected to Experience Continued Significant Growth
April 03, 2018
GB Sciences Signs Letter of Intent to Acquire NevadaPURE's Las Vegas Operations: Gaining $16 Million in Annualized Revenues
March 27, 2018
GB Sciences, Inc. (OTCQB: GBLX) is extremely pleased to announce it has signed a letter of intent to purchase 100% of the ownership interests of NevadaPURE's Las Vegas operation for $28 million in cash...
Legal and Medical Cannabis Industries Are Set to Grow
March 22, 2018